Explore the latest news from Khondrion and its team.
Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that its CEO Prof. dr. Jan Smeitink will present first results of Khondrion’s KHENERGY study at the Dutch Life Sciences Conference in Oss, The Netherlands, on November 22 at 10 am.
New Patents granted for Khondrion’s mitochondrial disease lead compound KH176 NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical...
Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical...
THE KHENERGYC STUDY: European Union EFRO grant to boost the development of Khondrion’s KH176 for children with mitochondrial...
Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes...
Press Release New EU research project REMIX joins forces between universities’ research facilities and Khondrion New EU...
Cognition is an important function of the brain so we can gain knowledge and understanding. These mental processes include thinking, knowing,...
Classic MELAS syndrome (Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes), MIDD (maternally inherited diabetes mellitus...
1. Tell us all about your career before joining Khondrion I studied pharmacology and molecular biology at the University of Strasbourg in France,...
Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the Mitochondrial Medicine conference held from 11-13 December 2019 at the...
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
Reflections on SSIEM annual symposium 2019 – Building Bridges Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the...
